Gap finder

Search review questions

Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.

Population

Intervention or exposure

Comparison

Outcome

Any field or review title

Field or topic

Source

Review versions

2,653 questions in 194 reviews · Gynaecology and Fertility

current versions

No studies 531 · 20%Ungraded 76 · 2.9%Very low 826 · 31.1%Low 855 · 32.2%Moderate 341 · 12.9%High 24 · 0.9%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Question	Effect	Evidence	Status / GRADE
Combined continuous hormone therapy (HT) vs placebo Coronary events (MI or cardiac death) · relatively healthy postmenopausal women Long‐term hormone therapy for perimenopausal and postmenopausal women (2017) · Cochrane	RR 1.89 [1.15, 3.1]	2 studies · 20993 participants	Moderate
Oestrogen‐only hormone therapy (HT) vs placebo Venous thromboembolism (DVT or PE) · relatively healthy postmenopausal women Long‐term hormone therapy for perimenopausal and postmenopausal women (2017) · Cochrane	RR 2.22 [1.12, 4.39]	1 study · 10739 participants	Moderate
Oestrogen‐only hormone therapy (HT) vs placebo Venous thromboembolism (DVT or PE): CEE 0.625 mg (moderate dose) · relatively healthy postmenopausal women Long‐term hormone therapy for perimenopausal and postmenopausal women (2017) · Cochrane	RR 1.32 [1, 1.74]	1 study · 10739 participants	Moderate
Oestrogen‐only hormone therapy (HT) vs placebo Breast cancer · relatively healthy postmenopausal women Long‐term hormone therapy for perimenopausal and postmenopausal women (2017) · Cochrane	RR 0.79 [0.61, 1.01]	1 study · 10739 participants	Moderate
Oestrogen‐only hormone therapy (HT) vs placebo Gallbladder disease · relatively healthy postmenopausal women Long‐term hormone therapy for perimenopausal and postmenopausal women (2017) · Cochrane	RR 1.78 [1.42, 2.24]	1 study · 8376 participants	Moderate
Oestrogen‐only hormone therapy (HT) vs placebo All clinical fractures · relatively healthy postmenopausal women Long‐term hormone therapy for perimenopausal and postmenopausal women (2017) · Cochrane	RR 0.73 [0.65, 0.8]	1 study · 10739 participants	Moderate
Combined continuous hormone therapy (HT) vs placebo Stroke · relatively healthy postmenopausal women Long‐term hormone therapy for perimenopausal and postmenopausal women (2017) · Cochrane	RR 146 [1.02, 2.09]	2 studies · 17585 participants	Moderate
Combined continuous hormone therapy (HT) vs placebo Venous thromboembolism (DVT or PE) · relatively healthy postmenopausal women Long‐term hormone therapy for perimenopausal and postmenopausal women (2017) · Cochrane	RR 4.28 [2.49, 7.34]	2 studies · 20993 participants	Moderate
Combined continuous hormone therapy (HT) vs placebo Breast cancer · relatively healthy postmenopausal women Long‐term hormone therapy for perimenopausal and postmenopausal women (2017) · Cochrane	RR 1.27 [1.03, 1.56]	1 study · 16608 participants	Moderate
Combined continuous hormone therapy (HT) vs placebo Death from lung cancer · relatively healthy postmenopausal women Long‐term hormone therapy for perimenopausal and postmenopausal women (2017) · Cochrane	RR 1.74 [1.18, 2.55]	1 study · 16608 participants	Moderate
Combined continuous hormone therapy (HT) vs placebo Gallbladder disease · relatively healthy postmenopausal women Long‐term hormone therapy for perimenopausal and postmenopausal women (2017) · Cochrane	RR 1.64 [1.3, 2.06]	1 study · 14203 participants	Moderate
Combined continuous hormone therapy (HT) vs placebo All clinical fractures · relatively healthy postmenopausal women Long‐term hormone therapy for perimenopausal and postmenopausal women (2017) · Cochrane	RR 0.78 [0.71, 0.86]	1 study · 16608 participants	Moderate
Oestrogen‐only hormone therapy (HT) vs placebo Coronary events (MI or cardiac death) · relatively healthy postmenopausal women Long‐term hormone therapy for perimenopausal and postmenopausal women (2017) · Cochrane	RR 0.94 [0.78, 1.13]	1 study · 10739 participants	Moderate
Oestrogen‐only hormone therapy (HT) vs placebo Stroke · relatively healthy postmenopausal women Long‐term hormone therapy for perimenopausal and postmenopausal women (2017) · Cochrane	RR 1.33 [1.06, 1.67]	1 study · 10739 participants	Moderate
Antibiotics vs placebo Total postoperative infections ‐ early and late · women having elective vaginal hysterectomy Antibiotic prophylaxis for elective hysterectomy (2017) · Cochrane	RR 0.28 [0.19, 0.4]	4 studies · 293 participants	Low
Antibiotics vs placebo Pelvic infection · women having elective abdominal hysterectomy Antibiotic prophylaxis for elective hysterectomy (2017) · Cochrane	RR 0.5 [0.35, 0.71]	11 studies · 1883 participants	Moderate
Antibiotics vs placebo Other serious infections · women having elective abdominal hysterectomy Antibiotic prophylaxis for elective hysterectomy (2017) · Cochrane	RR 0.44 [0.12, 1.69]	2 studies · 476 participants	Very low
Antibiotics vs placebo Postoperative fever · women having elective abdominal hysterectomy Antibiotic prophylaxis for elective hysterectomy (2017) · Cochrane	RR 0.59 [0.5, 0.7]	11 studies · 2394 participants	Moderate
Antibiotics vs placebo Total adverse effects · women having elective abdominal hysterectomy Antibiotic prophylaxis for elective hysterectomy (2017) · Cochrane	RR 1.8 [0.62, 5.18]	2 studies · 430 participants	Very low
Intervention NR Total postoperative infections ‐ early and late Urinary tract infection Pelvic infection Other serious infections Postoperative fever · women having elective vaginal hysterectomy Antibiotic prophylaxis for elective hysterectomy (2017) · Cochrane	no estimate extracted	2 studies · 470 participants	Very low
Intervention NR Total adverse effects · women having elective vaginal hysterectomy Antibiotic prophylaxis for elective hysterectomy (2017) · Cochrane	no estimate extracted	2 studies · 451 participants	Very low
Intervention NR Total postoperative infections ‐ early and late Abdominal wound infection Urinary tract infection Pelvic infection Other serious infections Postoperative fever · women having elective abdominal hysterectomy Antibiotic prophylaxis for elective hysterectomy (2017) · Cochrane	no estimate extracted	1 study · 220 participants	Very low
Intervention NR Total adverse effects · women having elective abdominal hysterectomy Antibiotic prophylaxis for elective hysterectomy (2017) · Cochrane	no estimate extracted	NR	No studies
Antibiotics vs placebo Urinary tract infection · women having elective vaginal hysterectomy Antibiotic prophylaxis for elective hysterectomy (2017) · Cochrane	RR 0.58 [0.43, 0.77]	8 studies · 1473 participants	Moderate
Antibiotics vs placebo Pelvic infection · women having elective vaginal hysterectomy Antibiotic prophylaxis for elective hysterectomy (2017) · Cochrane	RR 0.28 [0.2, 0.39]	11 studies · 1693 participants	Moderate
Antibiotics vs placebo Other serious infections · women having elective vaginal hysterectomy Antibiotic prophylaxis for elective hysterectomy (2017) · Cochrane	RR 0.2 [0.01, 4.1]	1 study · 146 participants	Very low
Antibiotics vs placebo Postoperative fever · women having elective vaginal hysterectomy Antibiotic prophylaxis for elective hysterectomy (2017) · Cochrane	RR 0.43 [0.34, 0.54]	9 studies · 1562 participants	Moderate
Antibiotics vs placebo Total adverse effects ‐ not reported · women having elective vaginal hysterectomy Antibiotic prophylaxis for elective hysterectomy (2017) · Cochrane	no estimate extracted	NR	No studies
Antibiotics vs placebo Total postoperative infections ‐ early and late · women having elective abdominal hysterectomy Antibiotic prophylaxis for elective hysterectomy (2017) · Cochrane	RR 0.38 [0.21, 0.67]	1 study · 158 participants	Low
Antibiotics vs placebo Abdominal wound infection · women having elective abdominal hysterectomy Antibiotic prophylaxis for elective hysterectomy (2017) · Cochrane	RR 0.51 [0.36, 0.73]	11 studies · 2247 participants	Moderate
Antibiotics vs placebo Urinary tract infection · women having elective abdominal hysterectomy Antibiotic prophylaxis for elective hysterectomy (2017) · Cochrane	RR 0.41 [0.31, 0.53]	11 studies · 2705 participants	Moderate
Glucocorticoid supplementation vs placebo Live birth rate · Patients undergoing IVF or ICSI Glucocorticoid supplementation during ovarian stimulation for IVF or ICSI (2017) · Cochrane	OR 1.08 [0.45, 2.58]	2 studies · 212 participants	Low
Glucocorticoid supplementation vs placebo Clinical pregnancy rate per woman/couple · Patients undergoing IVF or ICSI Glucocorticoid supplementation during ovarian stimulation for IVF or ICSI (2017) · Cochrane	OR 1.69 [0.98, 2.9]	2 studies · 310 participants	Low
Glucocorticoid supplementation vs placebo Multiple pregnancy rate per woman/couple · Patients undergoing IVF or ICSI Glucocorticoid supplementation during ovarian stimulation for IVF or ICSI (2017) · Cochrane	OR 3.32 [0.12, 91.6]	1 study · 20 participants	Very low
Glucocorticoid supplementation vs placebo Miscarriage rate per woman · Patients undergoing IVF or ICSI Glucocorticoid supplementation during ovarian stimulation for IVF or ICSI (2017) · Cochrane	OR 1 [0.05, 18.57]	1 study · 20 participants	Very low
Glucocorticoid supplementation vs placebo OHSS per woman · Patients undergoing IVF or ICSI Glucocorticoid supplementation during ovarian stimulation for IVF or ICSI (2017) · Cochrane	no estimate extracted	NR	No studies
Glucocorticoid supplementation vs placebo Side‐effects per woman · Patients undergoing IVF or ICSI Glucocorticoid supplementation during ovarian stimulation for IVF or ICSI (2017) · Cochrane	no estimate extracted	NR	No studies
NSAID vs placebo Pain relief · women with endometriosis Nonsteroidal anti‐inflammatory drugs for pain in women with endometriosis (2017) · Cochrane	OR 3.27 [0.61, 17.69]	1 study · 24 participants	Very low
NSAID vs placebo Unintended effects from treatment · women with endometriosis Nonsteroidal anti‐inflammatory drugs for pain in women with endometriosis (2017) · Cochrane	OR 0.46 [0.09, 2.47]	1 study · 24 participants	Very low
NSAID vs placebo Quality of life: not reported · women with endometriosis Nonsteroidal anti‐inflammatory drugs for pain in women with endometriosis (2017) · Cochrane	no estimate extracted	NR	No studies
NSAID vs placebo Effects on daily activities: not reported · women with endometriosis Nonsteroidal anti‐inflammatory drugs for pain in women with endometriosis (2017) · Cochrane	no estimate extracted	NR	No studies
NSAID vs placebo Absence from work or school: not reported · women with endometriosis Nonsteroidal anti‐inflammatory drugs for pain in women with endometriosis (2017) · Cochrane	no estimate extracted	NR	No studies
NSAID vs placebo Number of women requiring more invasive treatment: not reported · women with endometriosis Nonsteroidal anti‐inflammatory drugs for pain in women with endometriosis (2017) · Cochrane	no estimate extracted	NR	No studies
NSAID vs placebo Requirements for additional medication · women with endometriosis Nonsteroidal anti‐inflammatory drugs for pain in women with endometriosis (2017) · Cochrane	OR 0.12 [0.01, 1.29]	1 study · 24 participants	Very low
NSAID vs placebo Participant satisfaction with treatment: not reported · women with endometriosis Nonsteroidal anti‐inflammatory drugs for pain in women with endometriosis (2017) · Cochrane	no estimate extracted	NR	No studies
Recombinant luteinizing hormone (rLH) combined with recombinant follicle‐stimulating hormone (rFSH) vs rFSH alone Live birth rate · women undergoing ovarian stimulation in IVF or ICSI treatment cycles Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian… (2017) · Cochrane	OR 1.32 [0.85, 2.06]	4 studies · 499 participants	Very low
Recombinant luteinizing hormone (rLH) combined with recombinant follicle‐stimulating hormone (rFSH) vs rFSH alone OHSS incidence · women undergoing ovarian stimulation in IVF or ICSI treatment cycles Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian… (2017) · Cochrane	OR 0.38 [0.14, 1.01]	6 studies · 2178 participants	Low
Recombinant luteinizing hormone (rLH) combined with recombinant follicle‐stimulating hormone (rFSH) vs rFSH alone Ongoing pregnancy rate · women undergoing ovarian stimulation in IVF or ICSI treatment cycles Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian… (2017) · Cochrane	OR 1.2 [1.01, 1.42]	19 studies · 3129 participants	Moderate
Recombinant luteinizing hormone (rLH) combined with recombinant follicle‐stimulating hormone (rFSH) vs rFSH alone Miscarriage rate · women undergoing ovarian stimulation in IVF or ICSI treatment cycles Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian… (2017) · Cochrane	OR 0.93 [0.63, 1.36]	13 studies · 1711 participants	Moderate
Recombinant luteinizing hormone (rLH) combined with recombinant follicle‐stimulating hormone (rFSH) vs rFSH alone Cancellation rate for low response · women undergoing ovarian stimulation in IVF or ICSI treatment cycles Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian… (2017) · Cochrane	OR 0.77 [0.54, 1.1]	11 studies · 2251 participants	Low